A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Migraine Disorders
Interventions
BIOLOGICAL

Botulinum toxin type A Dose 1

Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.

BIOLOGICAL

Botulinum toxin type A Dose 2

Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.

DRUG

Placebo (Normal Saline)

Placebo (Normal Saline) intramuscular injections into specified muscles.

Trial Locations (22)

14609

Rochester Clinical Research, Inc, Rochester

15236

Jill Waldo, CCRC, Pittsburgh

32561

NW FL Clinical Research Group, LLC, Gulf Breeze

32819

Pediatric Neurology, PA, Orlando

33407

The Premiere Research Institute at Palm Beach Neurology, West Palm Beach

37203

Nashville Neuroscience Group, Nashville

46237

Josephson Wallack Munshower Neurology, P.C., Indianapolis

48104

Michigan Head Pain & Neurological Institute, Ann Arbor

65804

CORE (Center for Outpatient Research), Springfield

66212

CPFCC Neurology Research Department, Overland Park

73112

Lynn Health Science Institute, Oklahoma City

78258

Texas Association of Pediatric Neurology/Road Runner Research, San Antonio

83642

Advanced Clinical Research, Meridian

84107

Wasatch Clinical Research, Salt Lake City

85016

Phoenix Children's Hospital, Phoenix

89502

Renown Institution for Neurosciences, Reno

92056

The Research Center of Southern California, Oceanside

92835

Fullerton Neurology and Headache Center, Fullerton

94109

San Francisco Clinical Research Center, San Francisco

94305

Stanford Hospital and Clinics, Stanford

06824

Associated Neurologists of Southern CT, P.C., Fairfield

06905

New England Institute for Clinical Research, Stamford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY